Molecular and Cellular Aging
Michael Barish, Ph.D.
Michael Barish, Ph.D., professor in the Department of Developmental and Stem Cell Biology, received his Ph.D. from Stanford University. His team is using large-field imaging techniques to visualize tumor initiating cells in patient-derived tumor xenografts, and the spatial relationships of migrating tumor cells and the sites of proliferation and engraftment.
Michael Barish, Ph.D., professor in the Department of Developmental and Stem Cell Biology, received his Ph.D. from Stanford University. His team is using large-field imaging techniques to visualize tumor initiating cells in patient-derived tumor xenografts, and the spatial relationships of migrating tumor cells and the sites of proliferation and engraftment.
Wenyong Chen, Ph.D.
Wenyong Chen, Ph.D., associate professor in the Department of Cancer Biology, received his Ph.D. from the University of Alabama Birmingham. His laboratory is interested in understanding epigenetic regulation of hematopoietic stem cell aging, leukemia development and drug resistance in leukemia stem cells.
Wenyong Chen, Ph.D., associate professor in the Department of Cancer Biology, received his Ph.D. from the University of Alabama Birmingham. His laboratory is interested in understanding epigenetic regulation of hematopoietic stem cell aging, leukemia development and drug resistance in leukemia stem cells.
Mark LaBarge, Ph.D.
Mark LaBarge, Ph.D., professor in the Department of Population Sciences, received his Ph.D. from Stanford University. His team specializes in developing human cell systems to dissect the micro-environmental and tissue-level changes in breast that arise with age for understanding why aging is a major risk factor for breast cancer.
Mark LaBarge, Ph.D., professor in the Department of Population Sciences, received his Ph.D. from Stanford University. His team specializes in developing human cell systems to dissect the micro-environmental and tissue-level changes in breast that arise with age for understanding why aging is a major risk factor for breast cancer.
Yilun Liu, Ph.D.
Yilun Liu, Ph.D., professor and associate chair of the Department of Cancer Genetics and Epigenetics, received her Ph.D. from Yale University. Her team focuses on uncovering the molecular etiologies of developmental abnormalities, premature aging syndromes, malignancies and chemo-resistance by the clinical mutations of the RECQ DNA helicases.
Yilun Liu, Ph.D., professor and associate chair of the Department of Cancer Genetics and Epigenetics, received her Ph.D. from Yale University. Her team focuses on uncovering the molecular etiologies of developmental abnormalities, premature aging syndromes, malignancies and chemo-resistance by the clinical mutations of the RECQ DNA helicases.
Mina Sedrak, M.D., M.S.
Mina Sedrak, M.D., M.S., assistant professor in the Department of Medical Oncology & Therapeutics Research, received his M.D. from Rush Medical College. He is focused on examining barriers to clinical trial participation for older adults with cancer as a way to improve evidence based cancer therapy for this population.
Mina Sedrak, M.D., M.S., assistant professor in the Department of Medical Oncology & Therapeutics Research, received his M.D. from Rush Medical College. He is focused on examining barriers to clinical trial participation for older adults with cancer as a way to improve evidence based cancer therapy for this population.